Diabetes mellitus and risk of prostate cancer: An updated meta-analysis based on 12 case-control and 25 cohort studies

Acta Diabetologica

Volumn 49, Issue 1 SUPPL., 2012, Pages

  Zhang, Fan ^a   Yang, Yuan ^b   Skrip, Laura ^c   Hu, Dayi ^b   Wang, Yang ^a   Wong, Chunguang ^a   Qiu, Jingfu ^a   Lei, Han ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c YALE UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Meta analysis; Prostate cancer

Indexed keywords

INSULIN;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; INSULIN TREATMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PUBLISHING; REGISTER; RISK ASSESSMENT; STATISTICAL MODEL; SYSTEMATIC REVIEW; UNITED STATES; ADULT; AGED; INCIDENCE; MALE; META ANALYSIS; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES COMPLICATIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84878895723     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-012-0439-5     Document Type: Article

References (67)

1. Deng L, Gui Z, Zhao L, Wang J, Shen L (2012) Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 57(6):1576-1585
2. Wang P, Kang D, Cao W, Wang Y, Liu Z (2012) Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28(2):109-122
3. Ben Q, Xu M, Ning X et al (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 47(13):1928-1937
4. Onishi S, Takemoto M, Ishikawa T et al. (2012) Japanese diabetic patients with Werner syndrome exhibit high incidence of cancer. Acta Diabetol. doi: 10.1007/s00592-012-0424-z
5. Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47(2):87-95
6. Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47(6):1071-1078
7. Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2056-2062
8. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E (2009) A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer 100(11):1799-1805
9. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI (2009) Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort. Norway. Cancer Causes Control 20(7):1181-1192
10. Lee MY, Lin KD, Hsiao PJ, Shin SJ (2012) The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism 61(2):242-249
11. Tseng CH (2011) Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 34(3):616-621
12. Li Q, Kuriyama S, Kakizaki M et al (2010) History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control 21(7):1025-1032
13. Chodick G, Heymann AD, Rosenmann L et al (2010) Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 21(6):879-887
14. Moses KA, Utuama OA, Goodman M, Issa MM (2012) The association of diabetes and positive prostate biopsy in a US veteran population. Prostate Cancer Prostatic Dis 15(1):70-74
15. Ganesh B, Saoba SL, Sarade MN, Pinjari SV (2011) Risk factors for prostate cancer: an hospital-based case-control study from Mumbai, India. Indian J Urol 27(3):345-350
16. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, La Vecchia C (2011) The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 21(11):835-841
17. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ (2011) Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 14(4):326-331
18. Turner EL, Lane JA, Donovan JL et al (2011) Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). Int J Cancer 128(2):440-446
19. Baradaran N, Ahmadi H, Salem S et al (2009) The protective effect of diabetes mellitus against prostate cancer: role of sex hormones. Prostate 69(16):1744-1750
20. Pierce BL, Plymate S, Ostrander EA, Stanford JL (2008) Diabetes mellitus and prostate cancer risk. Prostate 68(10):1126-1132
21. Johnson JA, Bowker SL, Richardson K, Marra CA (2011) Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 54(9):2263-2271
22. Wallner LP, Morgenstern H, McGree ME et al (2011) The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int 107(6):929-935
23. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B (2010) The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 19(8):2088-2096
24. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA (2011) Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer 128(3):635-643
25. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169(8):937-945
26. Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398-1403
27. Leitzmann MF, Ahn J, Albanes D et al (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19(10):1267-1276
28. Darbinian JA, Ferrara AM, Van Den Eeden SK, Quesenberry CP Jr, Fireman B, Habel LA (2008) Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 17(3):628-635
29. Calton BA, Chang SC, Wright ME et al (2007) History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 18(5):493-503
30. Gong Z, Neuhouser ML, Goodman PJ et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15(10):1977-1983
31. Velicer CM, Dublin S, White E (2007) Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 10(1):46-51
32. Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164(11):1094-1102
33. Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54(1):25-31
34. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305
35. Hitron A, Adams V, Talbert J, Steinke D (2012) The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 36(4):e243-e250
36. Chang CH, Toh S, Lin JW et al (2011) Cancer risk associated with insulin glargine among adult type 2 diabetes patients-a nationwide cohort study. PLoS ONE 6(6):e21368
37. Ben Sahra I, Laurent K, Giuliano S et al (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70(6):2465-2475
38. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 25(1):41-49
39. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
40. Little J, Bradley L, Bray MS et al (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156:300-310
41. Crowther M, Lim W, Crowther MA (2010) Systematic review and meta-analysis methodology. Blood 116(17):3140-3146
42. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
43. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
44. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
45. Tavani A, Gallus S, Bertuzzi M et al (2005) Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 47(3):313-317
46. González-Pérez A, García Rodríguez LA (2005) Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 16(9):1055-1058
47. Coker AL, Sanderson M, Zheng W, Fadden MK (2004) Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer 90(11):2171-2175
48. Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM (2004) History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 159(10):978-982
49. Tavani A, Gallus S, Bosetti C et al (2002) Diabetes and the risk of prostate cancer. Eur J Cancer Prev 11(2):125-128
50. Rosenberg DJ, Neugut AI, Ahsan H, Shea S (2002) Diabetes mellitus and the risk of prostate cancer. Cancer Invest 20(2):157-165
51. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE (2005) Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 161(2):147-152
52. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO (2002) Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 102(3):258-261
53. Will JC, Vinicor F, Calle EE (1999) Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 10(3):313-318
54. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1998) Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 9(1):3-9
55. Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360-1365
56. Smith GD, Egger M, Shipley MJ, Marmot MG (1992) Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 136:1110-1114
57. Coughlin SS, Neaton JD, Sengupta A (1996) Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the multiple risk factor intervention trial. Am J Epidemiol 143:1002-1006
58. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88(16):1118-1126
59. Corona G, Monami M, Rastrelli G et al (2011) Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 34(6 Pt 1):528-540
60. Gatenby VK, Kearney MT (2010) The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. Expert Opin Ther Targets 14(12):1333-1342
61. Cohen P, Peehl DM, Lamson G, Rosenfeld RG (1991) Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401-407
62. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416-2429
63. Hsing AW, Chua S Jr, Gao YT et al (2001) Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93:783-789
64. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG (2002) Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 50:1-3
65. Perseghin G, Calori G, Lattuada G et al. (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol. doi: 10.1007/s00592-011-0361-2
66. Wells GA, Shea B, O'Connell D et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm Cited 19 June 2012
67. Yang X, So WY, Ma RC et al. (2012) Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Acta Diabetol. doi: 10.1007/s00592-012-0409-y